{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:11:23Z","timestamp":1779804683130,"version":"3.53.1"},"posted":{"date-parts":[[2026,5,26]]},"group-title":"In Review","reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,9]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have transformed the management of obesity and type 2 diabetes. Emerging reports describe accelerated facial soft-tissue deflation and periorbital changes among treated patients, often referred to as \"Ozempic face.\" Given the thin skin and minimal subcutaneous tissue of the upper eyelid, rapid weight loss may exacerbate dermatochalasis and increase demand for surgical correction. This study evaluates whether GLP-1 RA therapy is associated with an increased rate of upper eyelid blepharoplasty.\nMethods\n A retrospective cohort study was conducted using the TriNetX Research Network. Female adults aged 18 or older with diabetes mellitus and essential hypertension between January 2015 and January 2020 were identified. Patients prescribed GLP-1 RA comprised the exposure cohort; patients without GLP-1 RA served as controls. Follow-up extended up to five years. The primary outcome was upper eyelid blepharoplasty. Propensity score matching (1:1 nearest neighbor) was performed for age, race, BMI, and comorbidities. Kaplan\u2013Meier survival analysis and Cox proportional hazards modeling were performed. A secondary analysis compared patients achieving weight loss without GLP-1 RA to matched controls with stable BMI.\nResults\n A total of 821,792 eligible female patients were identified, of whom 28,970 received GLP-1 RA therapy. After propensity score matching, 23,349 patients remained in each cohort. At five-year follow-up, 96 GLP-1 RA users (0.41%) underwent blepharoplasty compared with 36 controls (0.15%). GLP-1 RA use was associated with an increased hazard of blepharoplasty (hazard ratio 2.22; 95% confidence interval 1.51\u20133.26; p\u2009&lt;\u20090.001). Kaplan\u2013Meier analysis demonstrated shorter time to surgery among GLP-1 RA users. In the secondary analysis, non-GLP-1 RA weight loss was not associated with increased blepharoplasty incidence (hazard ratio 1.31; 95% confidence interval 0.89\u20131.93; p\u2009=\u20090.56).\nConclusions\n GLP-1 receptor agonist use is associated with a significantly increased rate and earlier timing of upper eyelid blepharoplasty compared with matched controls. Weight loss alone did not demonstrate the same association, suggesting a distinct pattern of facial remodeling related to GLP-1 RA therapy. As pharmacologic weight loss expands, plastic surgeons should anticipate increased demand for periorbital rejuvenation and counsel patients accordingly.<\/p>","DOI":"10.21203\/rs.3.rs-9665910\/v1","type":"posted-content","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:27:36Z","timestamp":1779802056000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty"],"prefix":"10.21203","author":[{"given":"Victor F. A.","family":"Almeida","sequence":"first","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ha","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Duraes","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoela","family":"Dantas","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Hashem","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risal S.","family":"Djohan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana F. R.","family":"Duraes","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Haykal, D., Hersant, B., Cartier, H., & Meningaud, J.\u2011P. (2025). The role of GLP\u20111 agonists in esthetic medicine: Exploring the impact of semaglutide on body contouring and skin health. Journal of Cosmetic Dermatology, 24, e16716. https:\/\/doi.org\/10.1111\/jocd.16716","DOI":"10.1111\/jocd.16716"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Tay, J. Q. (2023). Ozempic face: A new challenge for facial plastic surgeons. Journal of Plastic, Reconstructive & Aesthetic Surgery, 81, 97\u201398. https:\/\/doi.org\/10.1016\/j.bjps.2023.04.057","DOI":"10.1016\/j.bjps.2023.04.057"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Stanton, E. W., Manasyan, A., Banerjee, R., Hong, K., Koesters, E., & Daar, D. A. (2025). Glucagon\u2011like peptide\u20111 agonists: A practical overview for plastic and reconstructive surgeons. Annals of Plastic Surgery, 94(1), 121\u2013127. https:\/\/doi.org\/10.1097\/SAP.0000000000004089","DOI":"10.1097\/SAP.0000000000004089"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Khong, J., Suresh, R., Park, K. E., & Soltanian, H. (2025). New contours, different risks: A 9\u2011year comparison of trends and postoperative complications in patients undergoing aesthetic surgery with previous bariatric surgery vs glucagon\u2011like peptide\u20111 receptor agonist use. Aesthetic Surgery Journal, 00(0), 1\u20137. https:\/\/doi.org\/10.1093\/asj\/sjaf131","DOI":"10.1093\/asj\/sjaf131"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Ridha, Z., Fabi, S. G., Zubair, R., & Dayan, S. H. (2024). Decoding the implications of glucagon\u2011like peptide\u20111 receptor agonists on accelerated facial and skin aging. Aesthetic Surgery Journal, 44(11), NP809\u2013NP818. https:\/\/doi.org\/10.1093\/asj\/sjae132","DOI":"10.1093\/asj\/sjae132"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Sharma, R. K., Vittetoe, K. L., Barna, A. J., Takkouche, S., Varelas, A. N., Yang, S. F., Stephan, S. J., & Patel, P. N. (2025). Radiographic midfacial volume changes in patients on GLP\u20111 agonists. Otolaryngology\u2013Head & Neck Surgery, 173(2), 360\u2013366. https:\/\/doi.org\/10.1002\/ohn.1209","DOI":"10.1002\/ohn.1209"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., La Placa, M., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. (2025). Benefit\u2011risk assessment of GLP\u20111 receptor agonists: Implications for dermatologists and plastic surgeons. Dermatology and Therapy. Advance online publication. https:\/\/doi.org\/10.1007\/s13555-025-01537-5","DOI":"10.1007\/s13555-025-01537-5"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Albanese, R., Tomaselli, F., & Tambasco, D. (2025). GLP\u20111 induced weight loss and plastic surgery: Time for a multidisciplinary dialogue. Plastic and Reconstructive Surgery. Advance online publication. https:\/\/doi.org\/10.1097\/PRS.0000000000012485","DOI":"10.1097\/PRS.0000000000012485"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Humphrey, C. D., & Lawrence, A. C. (2023). Implications of Ozempic and other GLP\u20111 receptor agonists for facial plastic surgeons. Facial Plastic Surgery, 39, 719\u2013721. https:\/\/doi.org\/10.1055\/a-2148-6321","DOI":"10.1055\/a-2148-6321"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Mansour, M. R., Hannawa, O. M., Yaldo, M. M., Nageeb, E. M., & Chaiyasate, K. (2024). The rise of \u201cOzempic Face\u201d: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP\u20111 agonists. Journal of Plastic, Reconstructive & Aesthetic Surgery, 96, 225\u2013227. https:\/\/doi.org\/10.1016\/j.bjps.2024.07.051","DOI":"10.1016\/j.bjps.2024.07.051"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Toms, J. A., O'Neill, E., Wiegmann, A. L., Adepoju, J., & Raj, M. S. (2024). Prevalence patterns of body contouring procedures among injectable glucagon\u2011like peptide\u20111 receptor agonist users. Aesthetic Surgery Journal, 44(10), 1072\u20131079. https:\/\/doi.org\/10.1093\/asj\/sjae085","DOI":"10.1093\/asj\/sjae085"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Schelke, L., Harris, S., Cartier, H., Alfertshofer, M., Doestzada, M., Cotofana, S., & Velthuis, P. J. (2023). Treating facial overfilled syndrome with impaired facial expression\u2014Presenting clinical experience with ultrasound imaging. Journal of Cosmetic Dermatology, 22(12), 3252\u20133260. https:\/\/doi.org\/10.1111\/jocd.16013","DOI":"10.1111\/jocd.16013"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., et al. (2021). Racial, ethnic, and socioeconomic inequities in glucagon\u2011like peptide\u20111 receptor agonist use among patients with diabetes in the US. JAMA Health Forum, 2(12), e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182","DOI":"10.1001\/jamahealthforum.2021.4182"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. De Biasio F, Miotti G, Zingaretti N, Castriotta L, Parodi PC. Study on the Aging Dynamics of the Periorbital Region: From Observation to Knowledge of Physiopathology. Ophthalmic Plast Reconstr Surg. 2019;35(4):333\u2013341. doi:10.1097\/IOP.0000000000001247","DOI":"10.1097\/IOP.0000000000001247"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Ha RY, Nojima K, Adams WP Jr, Brown SA. Analysis of facial skin thickness: defining the relative thickness index. Plast Reconstr Surg. 2005;115(6):1769\u20131773. doi:10.1097\/01.prs.0000161682.63535.9b","DOI":"10.1097\/01.PRS.0000161682.63535.9B"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Kim KK, Granick MS, Baum GA, et al. American Society of Plastic Surgeons Evidence-Based Clinical Practice Guideline: Eyelid Surgery for Upper Visual Field Improvement. Plast Reconstr Surg. 2022;150(2):419e-434e. doi:10.1097\/PRS.0000000000009329","DOI":"10.1097\/PRS.0000000000009329"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Ansari Z, Singh R, Alabiad C, Galor A. Prevalence, risk factors, and morbidity of eye lid laxity in a veteran population. Cornea. 2015;34(1):32\u201336. doi:10.1097\/ICO.0000000000000286","DOI":"10.1097\/ICO.0000000000000286"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021). Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in therapy, 38(6), 2821\u20132839. https:\/\/doi.org\/10.1007\/s12325-021-01710-0","DOI":"10.1007\/s12325-021-01710-0"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023). Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, 33(3), 159\u2013166. https:\/\/doi.org\/10.1016\/j.tcm.2021.12.008","DOI":"10.1016\/j.tcm.2021.12.008"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Vosoughi, K., Salman, R. R., et al. (2022). Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. Obesity Medicine, 35, 100456. https:\/\/doi.org\/10.1016\/j.obmed.2022.100456","DOI":"10.1016\/j.obmed.2022.100456"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F.; STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","DOI":"10.1056\/NEJMoa2032183"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y., Lv, F., Yang, W., & Ji, L. (2025). Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis. Diabetes, obesity & metabolism, 27(1), 259\u2013267. https:\/\/doi.org\/10.1111\/dom.16012","DOI":"10.1111\/dom.16012"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Sepe, A., Tchkonia, T., Thomou, T., Zamboni, M., & Kirkland, J. L. (2011). Aging and regional differences in fat cell progenitors - a mini-review. Gerontology, 57(1), 66\u201375. https:\/\/doi.org\/10.1159\/000279755","DOI":"10.1159\/000279755"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Cartwright, M. J., Tchkonia, T., & Kirkland, J. L. (2007). Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Experimental gerontology, 42(6), 463\u2013471. https:\/\/doi.org\/10.1016\/j.exger.2007.03.003","DOI":"10.1016\/j.exger.2007.03.003"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg. Published online September 17, 2025. doi:10.1001\/jamasurg.2025.3590","DOI":"10.1001\/jamasurg.2025.3590"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Wong, Z. Y., Ramasamy, P., Ingels, K. J. A. O., Parmar, C., Yang, W., Pouwels, S., & Upper Gastrointestinal Surgeons (TUGS), TUGS E-Health, Education, Surgical Publishing Research (TEESR) Group (2023). Changes of Facial Features After Bariatric Surgery: a Systematic Review. Obesity surgery, 33(1), 332\u2013338. https:\/\/doi.org\/10.1007\/s11695-022-06363-8","DOI":"10.1007\/s11695-022-06363-8"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Joudatt, L. L. C., Zotarelli-Filho, I. J., de Quadros, L. G., Lopes, A. C. P., de Lima Andr\u00e9, J., Joudatt, J., & Junior, R. L. K. (2023). Histological Skin Assessment of Patients Submitted to Bariatric Surgery: A Prospective Longitudinal Cohort Study. Obesity surgery, 33(3), 836\u2013845. https:\/\/doi.org\/10.1007\/s11695-023-06453-1","DOI":"10.1007\/s11695-023-06453-1"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403\u20131413. doi:10.1001\/jama.2021.1831","DOI":"10.1001\/jama.2021.1831"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol. 2015;402:43\u201350. doi:10.1016\/j.mce.2014.12.021","DOI":"10.1016\/j.mce.2014.12.021"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665910\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665910\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:27:42Z","timestamp":1779802062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9665910\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9665910\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,5,26]]},"subtype":"preprint"}}